Dr. Edgardo Santos' Group Interview with Heather McArthur, MD, MPH | Lajos Pusztai, MD, DPhil, FASCO | Mark Pegram, MD
Description
Interviews with Summit Director Edgardo S. Santos Castillero, MD, FACP, FASCO
NOSCM 2024 | New Orleans Summer Cancer Meeting
Dr. Edgardo Santos' Group Interview with Heather McArthur, MD, MPH | Lajos Pusztai, MD, DPhil, FASCO | Mark Pegram, MD
Dr. Edgardo Santos and his colleagues discussed recent advancements in breast cancer treatment. Dr. Heather McArthur highlighted the complex landscape of immunotherapy, particularly in triple-negative breast cancer, noting the FDA's approval of pembrolizumab. Dr. Lajos Pusztai emphasized the potential of pathologic complete response (PCR) as an accelerated approval endpoint and the shift towards new adjuvant therapies. Dr. Mark Pegram discussed the integration of novel therapies like CDK4/6 inhibitors and pertuzumab, noting the challenges of cost and access. The panel also addressed the broader challenges of insurance approval and the feasibility of new, expensive treatments.
United States
